Geron Corporation reports results for the quarter ended June 30 - Earnings Summary

Geron

05/08/2026 14:30

Geron Corporation GERN.OQ reported a quarterly adjusted loss of 2 cents​​ per share for the quarter ended June 30, identical to the same quarter last year.  The mean expectation of five analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -1 cents to
Revenue rose 17.2% to $57.48 million from a year ago; analysts expected $55.31 million. 
Geron Corporation's reported EPS for the quarter was a loss of 2 cents​.
The company reported a quarterly loss of $16.68 million.
Geron Corporation shares had risen by 4.7% this quarter and gained 1.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 12.5% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Geron Corporation is $4.00, about 66.5% above its last closing price of $1.34
This summary was machine generated from LSEG data August 5 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.01
-0.02
Missed
Mar. 31 2026 
-0.02
-0.01
Beat
Dec. 31 2025 
-0.03
-0.02
Beat
Sep. 30 2025 
-0.03
-0.03
Met